Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD) in Hospitalized Patients With Moderate COVID-19

Next Previous
Trial Profile

A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD) in Hospitalized Patients With Moderate COVID-19

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STI 1499 (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sorrento Therapeutics

Most Recent Events

  • 06 Jan 2021 Planned End Date changed from 1 Feb 2021 to 1 Jan 2021.
  • 06 Jan 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Jan 2021.
  • 06 Jan 2021 Status changed from recruiting to withdrawn prior to enrolment due to Difficulty in recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top